Advanced Search
MyIDEAS: Login to save this paper or follow this series

R&D in the Belgian Pharmaceutical Sector


Author Info

  • Helga De Doncker

    (National Bank of Belgium, Microeconomic Information Department)

Registered author(s):


    The Belgian pharmaceutical sector has been accorded a leading role in the attainment of the R&D investment targets which the EU Member States set themselves as part of the Lisbon strategy. To gain a better insight into that sector’s research activities, the NBB conducted an ad hoc survey in 2005, covering pharmaceutical companies active in Belgium in the field of research, production and distribution of drugs for human use. The analysis of the information obtained from that survey makes up the main body of this working paper. The survey results do not only confirm the importance of the research activities conducted by Belgian establishments, but also indicate the frequent cooperation with other research centres and the crucial importance of expertise as a factor influencing the location of such activities in Belgium. The breakdown of the survey results by kind of establishment on the basis of the type of activities conducted in Belgium reveals further clear differences of emphasis in the nature of the R&D activities pursued in Belgium and divergences in the scale of the resources used. The paper also comprises a number of annexes giving additional information on the sector. More particularly, they deal with added value and employment, the indirect effects and profitability of the pharmaceutical companies, and background information on reference reimbursement of drugs.

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL:
    Download Restriction: no

    Bibliographic Info

    Paper provided by National Bank of Belgium in its series Working Paper Document with number 106.

    as in new window
    Length: 80 pages
    Date of creation: Dec 2006
    Date of revision:
    Handle: RePEc:nbb:docwpp:200612-1

    Contact details of provider:
    Postal: Boulevard de Berlaimont 14, B-1000 Bruxelles
    Phone: (+ 32) (0) 2 221 25 34
    Fax: (+ 32) (0) 2 221 31 62
    Web page:
    More information through EDIRC

    Related research

    Keywords: pharmaceutical industry; R&D; reference reimbursement;

    Find related papers by JEL classification:

    This paper has been announced in the following NEP Reports:


    No references listed on IDEAS
    You can help add them by filling out this form.



    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.


    Access and download statistics


    When requesting a correction, please mention this item's handle: RePEc:nbb:docwpp:200612-1. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ().

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.